-
Mashup Score: 0Testing a new measure of lupus improvement that encompasses the patients’ perspectives and doctors’ evaluations | Lupus Science and Medicine Podcast - 7 month(s) ago
Dr. Anna Wolska from the Lupus Foundation of America interviews Drs. Anca Askanase and Joan Merrill, the developers of the LFA-REAL tool. Together, they discuss the importance of using a tool like LFA-REAL to understand how clinician and patient reported outcomes are essential for understanding efficacy and effectiveness of experimental therapeutics developed to treat people living with lupus. Read the article: http://dx.doi.org/10.1136/lupus-2022-000875
Source: lupusbmj.podbean.comCategories: Latest Headlines, RheumatologyTweet
-
Mashup Score: 0Experimental Assessment of Intestinal Damage in Controlled Donation After Circulatory Death for Visceral Transplantation - 1 year(s) ago
There is an urgent need to address the shortage of potential multivisceral grafts in order to reduce the average time in waiting list. Since donation after circulatory death (DCD) has been successfully employed for other solid organs, a thorough evaluation of the use of intestinal grafts from DCD is warranted. Here, we have generated a model of Maastricht III DCD in rodents, focusing on the…
Source: FrontiersCategories: Latest Headlines, TransplantationTweet-
A #novel #experimental model of Maastricht III #DCD for the evaluation of the quality of transplantable grafts https://t.co/VSLOVC9TAQ https://t.co/akTRYGESx4
-
-
Mashup Score: 0Experimental Assessment of Intestinal Damage in Controlled Donation After Circulatory Death for Visceral Transplantation - 1 year(s) ago
There is an urgent need to address the shortage of potential multivisceral grafts in order to reduce the average time in waiting list. Since donation after circulatory death (DCD) has been successfully employed for other solid organs, a thorough evaluation of the use of intestinal grafts from DCD is warranted. Here, we have generated a model of Maastricht III DCD in rodents, focusing on the…
Source: FrontiersCategories: Latest Headlines, TransplantationTweet-
A #novel #experimental model of Maastricht III #DCD that may contribute to evaluation of the quality of these grafts for transplantation in the clinical practice https://t.co/VSLOVC9TAQ https://t.co/wlIiXv8ZEi
-
-
Mashup Score: 0
December 1, 2022 — Scientists at the Centro Nacional de Investigaciones Cardiovasculares (CNIC) have identified a new therapeutic target for the prevention of heart failure linked to aortic stenosis. The study was led by Dr. Borja Ibáñez, Clinical Research Director at the CNIC, cardiologist at Hospital Universitario Fundación Jiménez Díaz, and member of the Spanish cardiovascular research…
Source: DAICCategories: Cardiologists, Latest HeadlinesTweet-
@DAICeditor @CNIC_CARDIO The #experimental #study, led by #researchers at the #CNIC, shows that boosting the expression of this #adrenalin_receptor in heart cells improves #mitochondrial function in the #heart: https://t.co/EPBTI8u67X
-
-
Mashup Score: 0The Novel Lysosomal Autophagy Inhibitor (ROC-325) Ameliorates Experimental Pulmonary Hypertension - PubMed - 1 year(s) ago
These data indicate that ROC-325 is a promising novel agent for the treatment of PH that inhibits autophagy, downregulates HIF levels, and increases nitric oxide production.
Source: PubMedCategories: Latest Headlines, PulmonologyTweet-
The #Novel #Lysosomal #Autophagy #Inhibitor (ROC-325) Ameliorates #Experimental #Pulmonary #Hypertension #PH https://t.co/vCDe6I9M5d https://t.co/3UG7ZgDB7V
-
-
Mashup Score: 10Access to early-phase clinical trials in older patients with cancer in France: the EGALICAN-2 study - 2 year(s) ago
Access to clinical trials and especially early-phase trials (ECT) is an important issue in geriatric oncology. As cancer can be considered an age-rela…
Source: www.sciencedirect.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Factors associated with the administration of the #experimental treatment in patients older than 70 years with #cancer #ASCO22 @OncoAlert @OncologyAdvance @myESMO @cczielinski https://t.co/n0pqcv7MkC https://t.co/bvuoFOs6VD
-
-
Mashup Score: 3Experimental chewing gum may reduce virus spread; Booster shot protection may be longer lasting - 2 year(s) ago
The following is a summary of some recent studies on COVID-19. They include research that warrants further study to corroborate the findings and that has yet to be certified by peer review.
Source: ReutersCategories: Future of Medicine, Latest HeadlinesTweet-
I've seen #COVID #vaccines in the form of #nasal #sprays and #pills to treat the disease itself, but a chewing gum? "An #experimental #chewing #gum containing a protein that "traps" #coronavirus particles could limit the amount of #virus in saliva." 👉 https://t.co/mhQmEhtspr
-
-
Mashup Score: 4
Wuhan lab workers got sick in Fall 2019; Dr. Marc Siegel reacts on ‘Fox News @Night’
Source: Fox NewsCategories: Healthcare Professionals, Latest HeadlinesTweet-
State Department drops 'previously undisclosed' info on Wuhan lab https://t.co/W84SI5Rqox #Wuhan #coronavirus #bats @ShannonBream @foxnewsnight #experimental @USStateDepartm1
-
-
Mashup Score: 0Moderna Charging Much More for COVID-19 Vaccine Than Others - Infectious Disease Advisor - 4 year(s) ago
Moderna is charging $37 a dose for its experimental vaccine, which is far more than what other companies say they plan to charge for their vaccines.
Source: Infectious Disease AdvisorCategories: Infectious Disease, Latest HeadlinesTweet-
#Moderna is charging $37 a dose for its #experimental vaccine, which is far more than what other companies say they plan to charge for their #vaccines. #Pfizer #IDATwitter https://t.co/Qf9Bvuu4Lz
-
New #podcast- importance of using a #tool like #LFA-REAL to understand how #clinician & #patient reported #outcomes r essential for understanding #efficacy & #effectiveness of #experimental #therapeutics developed to treat people living w/ #lupus #SLE https://t.co/UXgCwZL5Ix